Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick R Appelbaum

Showing results (131-140 of 339) with videos related to

Pageof 34
Sort By:
Blood|October 5, 2013
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemiaSucha Nand, Megan Othus, John E Godwin, et al.
Cancer|June 3, 2015
Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemiaChristine M Gronseth, Scott E McElhone, Barry E Storer, et al.
Blood Advances|October 7, 2024
Measurable residual disease as predictor of post-day +100 relapses after allografting in adult AMLNaveed Ali, Megan Othus, Eduardo Rodríguez-Arbolí, et al.
Bone Marrow Transplantation|November 6, 2019
Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemiaAlexander P Hoffmann, Ashley L Besch, Megan Othus, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2006
Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapyAjay K Gopal, John M Pagel, Joseph G Rajendran, et al.
Blood|May 10, 2011
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605Mikkael A Sekeres, Holly Gundacker, Jeffrey Lancet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2015
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?Daisuke Araki, Brent L Wood, Megan Othus, et al.
Leukemia Research|February 7, 2018
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)Anjali S Advani, Hongli Li, Laura C Michaelis, et al.
Blood|August 14, 2008
Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantationAnn E Woolfrey, Uma Malhotra, Robert D Harrington, et al.
Blood|September 18, 2007
Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiencesMohamed L Sorror, Sergio Giralt, Brenda M Sandmaier, et al.
Pageof 34

Showing results (131-140 of 339) with videos related to

Sort By:
Pageof 34
Blood|October 5, 2013
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemiaSucha Nand, Megan Othus, John E Godwin, et al.
Cancer|June 3, 2015
Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemiaChristine M Gronseth, Scott E McElhone, Barry E Storer, et al.
Blood Advances|October 7, 2024
Measurable residual disease as predictor of post-day +100 relapses after allografting in adult AMLNaveed Ali, Megan Othus, Eduardo Rodríguez-Arbolí, et al.
Bone Marrow Transplantation|November 6, 2019
Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemiaAlexander P Hoffmann, Ashley L Besch, Megan Othus, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2006
Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapyAjay K Gopal, John M Pagel, Joseph G Rajendran, et al.
Blood|May 10, 2011
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605Mikkael A Sekeres, Holly Gundacker, Jeffrey Lancet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2015
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?Daisuke Araki, Brent L Wood, Megan Othus, et al.
Leukemia Research|February 7, 2018
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)Anjali S Advani, Hongli Li, Laura C Michaelis, et al.
Blood|August 14, 2008
Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantationAnn E Woolfrey, Uma Malhotra, Robert D Harrington, et al.
Blood|September 18, 2007
Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiencesMohamed L Sorror, Sergio Giralt, Brenda M Sandmaier, et al.
Pageof 34